Techpool aims to make signifcant changes, from its production lines to marketing, hardware and software.[Photo provided to chinadaily.com.cn]

Techpool Bio-Pharma Co has experienced tremendous changes in the past three years under the leadership of its new chief executive officer, transforming from a traditional private Chinese company to an international player.

Before Henry Lee took office in 2011, he was the senior executive in many leading companies in the pharmaceutical field, including Novartis and Eisai, with more than 20 years successful management experience in both China and the Asia-Pacific region.

Henry Lee,CEO of Techpool Bio-Pharma Co.[Photo provided to chinadaily.com.cn]

"I chose Techpool because of its huge development potential. Also, it had a pure, positive and healthy corporate culture, which was different from what I imagined that most of the Chinese private companies have complex and chaotic personal relations," Lee said.

It also had more comprehensive development than most Chinese private companies, with research and production capacities and a sales and marketing team nationwide.

However, "the business model the company implemented at that time could not support its sustainable development," he said.

In addition, the company also made significant changes, from its production lines to marketing, hardware and software.

"Last year, we realized production based on standards of the current good manufacture practices, or China new GMP standards, the first of its kind in Guangdong province where Techpool is headquartered," Lee said.

The China new GMP is a world-leading standard for pharmaceutical, medical device and food manufacturers in their production and testing of products. This is comparable with EU GMP standard.

"We also introduced the six sigma program to improve our management level," he said.